Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Third Rock Wise To The Opportunity In CNS; Stakes SAGE Therapeutics With $35 Million

This article was originally published in The Pink Sheet Daily

Executive Summary

The new company, co-founded by ex-Lilly executive Steven Paul, plans to move aggressively with its allosteric modulators, launching the first of several clinical programs within six months to a year.

You may also be interested in...

Financings Of The Fortnight: Rusnano Dodging Controversy, Transforming Into Private Equity Fund

The Russian sovereign fund is a major investor in several U.S. life sciences start-ups. Plus news on recent financings by SAGE Therapeutics, Macrogenics, G1 Therapeutics and TD1 Innovations.

Eyeing Epilepsy Franchise, SAGE Therapeutics Raises $20M

ARCH Venture Partners joined original investor Third Rock Ventures in backing the Cambridge, Mass., start-up with $20 million in Series B money. SAGE is concentrating its efforts on several compounds, including one to treat a type of epileptic seizure, which could represent the beginning of a larger epilepsy franchise.

With Shire Behind Him, Jonas Starts New Chapter At SAGE

The upbeat ex-Shire exec has moved on from his tumultuous break-up with the specialty pharma and is on day three in his new role as CEO of CNS start-up SAGE Therapeutics. He will focus on bringing CNS products forward for orphan indications.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts